Zyomyx of Hayward Calif., is now leading its prized protein biochip system to the starting gates.

The company has created an assay technology based on a chip containing high-density arrays of functional proteins, which it plans to market for use in drug discovery, biomarker identification, and target validation, and sell to large pharmas, biotechs, and the academic market. Zyomyx’s lead product, the protein profiling biochip system, has been available to early-access customers of the company since the summer, and should soon be launched to the target market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.